Share  |  Print  |  Facebook  |  Twitter  |  

Urge Your Senators to Support FY22 Prostate Cancer Research Funding

Please fill out the form below to tell your Senator to protect prostate cancer research funding by signing the Menendez-Crapo Dear Colleague letter!


  • Your Senators

Support $120M for Prostate Cancer Research Funding in FY2022

Dear [Congressman/Congresswoman],

I am contacting you to request your support for innovative translational prostate cancer research at the Department of Defense. In 2021, almost 250,000 men across the United States will be diagnosed with prostate cancer, and over 34,130 more will die of the disease - that's an almost 30 percent increase. With the help of targeted research at the Prostate Cancer Research Program, we can stop these trends.

Among American males, prostate cancer is the most-diagnosed cancer after skin cancer and is the second highest cancer-related cause of death. As someone who has been impacted by prostate cancer, I am asking you to sign the Dear Colleague letter to the Senate Appropriations Committee being circulated by U.S. Senators Robert Menendez (D-NJ) and Mike Crapo (R-ID).

The letter urges the Appropriations Subcommittee on Defense to provide $120 million in funding for the Department of Defense's (DoD) Peer Reviewed Prostate Cancer Research Program (PCRP) and recognize prostate cancer as a military relevant disease in the Fiscal Year 2022 DoD Appropriations bill.

As your constituent, I hope you will join U.S. Senators Crapo and Menendez in their effort to ensure this unique program can continue its groundbreaking work on behalf of prostate cancer patients. Please contact Diane Adamson in Sen. Bob Menendez's office ( or Rebecca Alcorn in Sen. Mike Crapo's office ( for more information or to sign-on.

Thank you in advance for your support,
[Your Name]
[Your Address]
[City, State ZIP]
[Your Email]

Your Contact Information

*Required fields


If you take action and have not already registered, you will receive periodic updates and communications from ZERO - The End of Prostate Cancer.